Trends of low-grade serous ovarian carcinoma in the United States

被引:29
|
作者
Matsuo, Koji [1 ,2 ]
Machida, Hiroko [3 ]
Grubbs, Brendan H. [4 ]
Sood, Anil K. [5 ]
Gershenson, David M. [5 ]
机构
[1] Univ Southern Calif, Div Gynecol Oncol, Dept Obstet & Gynecol, 2020 Zonal Ave,IRD520, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[3] Tokai Univ, Dept Obstet & Gynecol, Sch Med, Isehara, Kanagawa, Japan
[4] Univ Southern Calif, Div Maternal Fetal Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
关键词
D O I
10.3802/jgo.2018.29.e15
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the United States, ovarian carcinoma remains the most deadly gynecologic malignancy, and approximately 14,000 deaths are projected from the disease in 2017 [1]. Ovarian carcinoma comprises various histologic subtypes based on the cell of origin, with serous carcinoma being the most common subtype. Serous ovarian carcinomas are commonly grouped into 2 types based on histologic characteristics (high-grade and low-grade) [2,3]. Mounting evidence has shown that low-grade serous ovarian carcinoma (LGSOC) has distinct clinical and molecular differences from high-grade serous ovarian carcinoma (HGSOC) [4,5]. Unlike HGSOC, LGSOC is considered a rare tumor and has been understudied due to its low incidence. To date, there have been no population-based reports of LGSOC statistical trends. The objective of our study was to examine the temporal changes in the proportion of LGSOC among women with epithelial ovarian cancer.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] THE ROLE OF CHEMOTHERAPY IN LOW-GRADE SEROUS OVARIAN CARCINOMA: REPORT OF TWO CASES
    Moreira-Barros, J.
    Vaz, I.
    Gunthert, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1982 - 1982
  • [42] Racial and ethnic disparities among patients with low-grade serous ovarian carcinoma
    Siemon, J.
    George, S.
    Huang, M.
    Slomovitz, B. M.
    Pearson, J. M.
    Schlumbrecht, M. P.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 122 - 122
  • [43] Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
    Singer, G
    Oldt, R
    Cohen, Y
    Wang, BG
    Sidransky, D
    Kurman, RJ
    Shih, IM
    MODERN PATHOLOGY, 2003, 16 (01) : 211A - 211A
  • [44] Ovarian Low-grade Serous Carcinoma Likely Deriving from the Fallopian Tube
    Chen, Hao
    Wang, Yiying
    Mu, Jingyi
    Lea, Jayanthi
    Zheng, Wenxin
    MODERN PATHOLOGY, 2018, 31 : 412 - 412
  • [45] Characterizing FOLR1 expression in low-grade serous ovarian carcinoma
    Rushton, Tullia
    Krause, Harris Benjamin
    Elliott, Andrew
    Karnezis, Anthony
    Toboni, Michael Driscoll
    Thaker, Premal H.
    Braxton, David R.
    Oberley, Matthew James
    Gershenson, David Marc
    Armstrong, Deborah Kay
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Ovarian Low-grade Serous Carcinoma Involving the Cervix Mimicking a Cervical Primary
    Malpica, Anais
    Deavers, Michael T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2011, 30 (06) : 613 - 619
  • [47] Clinicodemographic Factors Influencing Outcomes in Patients With Low-Grade Serous Ovarian Carcinoma
    Schlumbrecht, Matthew P.
    Sun, Charlotte C.
    Wong, Karen N.
    Broaddus, Russell R.
    Gershenson, David M.
    Bodurka, Diane C.
    CANCER, 2011, 117 (16) : 3741 - 3749
  • [48] Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma
    Xing, Deyin
    Rahmanto, Yohan Suryo
    Zeppernick, Felix
    Hannibal, Charlotte G.
    Kjaer, Susanne K.
    Vang, Russell
    Shih, Ie-Ming
    Wang, Tian-Li
    HUMAN PATHOLOGY, 2017, 68 : 87 - 91
  • [49] Ovarian Low-grade Serous Carcinoma Likely Deriving from the Fallopian Tube
    Chen, Hao
    Wang, Yiying
    Mu, Jingyi
    Lea, Jayanthi
    Zheng, Wenxin
    LABORATORY INVESTIGATION, 2018, 98 : 412 - 412
  • [50] Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
    Singer, G
    Oldt, R
    Cohen, Y
    Wang, BG
    Sidransky, D
    Kurman, RJ
    Shih, IM
    LABORATORY INVESTIGATION, 2003, 83 (01) : 211A - 211A